ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
Rowan Miller(University College Hospital), Lucy Yates(Guy's Hospital), Alexandra Léary, Sohrab P. Shah(Memorial Sloan Kettering Cancer Center), Jos Jonkers(The Netherlands Cancer Institute), Xavier Matías‐Guiu(Instituto de Investigación Biomédica de Lleida), Serena Nik‐Zainal(University of Cambridge), Violeta Serra(Vall d'Hebron Institut de Recerca), Isabelle Ray‐Coquard(Centre Léon Bérard), Dale W. Garsed(Peter MacCallum Cancer Centre), Jonathan A. Ledermann(Cancer Institute (WIA)), Elizabeth M. Swisher(Seattle Cancer Care Alliance), Clare L. Scott(Royal Women's Hospital), David K. Chang(University of Glasgow), Christopher J. Lord(Institute of Cancer Research), David D.L. Bowtell(Peter MacCallum Cancer Centre)
Cited by 478
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k